Establishing data-derived adjustment factors from published pharmaceutical clinical trial data

Human and Ecological Risk Assessment (HERA)

Volumn 5, Issue 5, 1999, Pages 1059-1089

  Silverman, Keith C ^a   Naumann, Bruce D ^a   Holder, Daniel J ^a   Dixit, Rakesh ^a   Faria, Ellen C ^a   Sargent, Edward V ^a   Gallo, Michael A ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Acceptable daily intake; Pharmacokinetic; Uncertainty factors

Indexed keywords

EID: 22844453695     PISSN: 10807039     EISSN: None     Source Type: Journal    
DOI: 10.1080/10807039991289347     Document Type: Article

References (76)

1. Barnes, D. G. and Dourson, M. 1988. Reference Dose (RfD): Description and use in health risk assessments. Regul. Tox. Pharmacol. 8, 471-486.
2. Berthouex, P. M. and Brown, L. C. 1994. Seeing the shape of a distribution. In: Statistics for Environmental Engineers, pp. 41-47. Boca Raton, Florida, CRC Press.
3. Calabrese, E. J. 1985. Adjustment factors and interindividual variation. Regul. Toxicol. Pharmacol., 5, 190-196.
4. Dourson, M. L., Felter, S. P., and Robinson, D. 1996. Evolution of science-based uncertainty factors in noncancer risk assessment. Regul. Toxicol. Pharmacol. 24, 108-120.
5. Dourson, M. L. and Stara, J. F. 1983. Regulatory history and experimental support of uncertainty (safety) factors. Regul. Toxicol. Pharmacol. 3, 224-238.
6. Greenblatt, D. J., Sellers, E. M., and Shader, R. I. 1982. Drug disposition in old age. Med. Intell. 306, 18, 1061-1087.
7. Hattis, D. 1996. Variability in susceptibility - how big, how often, for what response to what agents? Environ. Toxicol. Pharmacol., 2, 135-145.
8. Hattis, D., Erdreich, L., and Ballew, M. 1987. Human variability in susceptibility to toxic chemicals - a preliminary analysis of pharmacokinetic data from normal volunteers. Risk Anal. 7, 415-426.
9. IPCS (International Programme on Chemical Safety). 1994. Assessing human health risk of chemicals: The derivation of guidance values for health-based exposure limits. Environmental Health Criteria 170. Genera, World Heatlh Organization.
10. National Research Council. 1994. Assessment of toxicity. In: Science and Judgement in Risk Assessment, pp. 56-67. Washington, DC, National Academy Press.
11. Naumann, B. D. and Sargent, E. V. 1997. Setting occupational exposure limits for pharmaceuticals. Occup. Med.: State of the Art Rev. 12, 1, 67-80.
12. Naumann, B. D., Weideman, P. A., Dixit, R., Grossman, S. J., Shen, C. F., and Sargent, E. V. 1997. Use of toxicokinetic and toxicodynamic data to reduce unceriainties when selling occupational exposure limits for pharmaceuticals. Hum. Ecol. Risk Assess., 3, 4, 555-565.
13. Naumann, B. D. and Weideman, P. A. 1995. Scientific basis for uncertainty factors used to establish occupational exposure limits for pharmaceutical active ingredients. Hum. Ecol. Risk Assess., 1, 590-613.
14. Renwick, A. G. and Lazarus, N. R. 1998. Human variability and noncancer risk assessment - an analysis of the default uncertainty factor. Regul. Toxicol. Pharmacol., 27, 3-20.
15. Renwick, A. G. 1993. Data-derived safety factors for the evaluation of food additives and environmental contaminants. Food Add. Contam., 10, 3, 275-305.
16. Renwick, A. G. 1991. Safety factors and establishment of acceptable daily intakes. Food Add. Contam., 8, 2, 135-150.
17. Sargent, E. V. and Kirk, G. D. 1988. Establishing airborne exposure control limits in the pharmaceutical industry. Am. Indus. Hygiene Assoc. J. 49(6): 309-313.
18. Truhaut, R. 1991 The concept of the acceptable daily intake: an historical review. Food Add. Contam., 8, 2, 151-162.
19. Ismail, Z., Triggs, E. J., Smithurst, B. A., and Parke, W. 1989. The pharmacokinetics of amiloride-hydrochlorothiazide combination in the young and elderly. Eur. J. Clin. Pharmacol. 37, 2, 167-171.
20. Jones, K. M., Liao, E., Hohneker, K., Turpin, S., Henry, M. M., Selinger, K., Hsyu, P., Boucher, R. C., Knowles, M. R., and Dukes, G. E. 1997. Pharmacokinetics of amiloride after inhalation and oral administration in adolescents and adults with cystic fibrosis. Pharmacotherapy 17, 2, 263-270.
21. Liao, E., Wood, R. E., Blair, K. C., Hsyu, P., Selinger, K., Church, N., Anderson, W., and Dukes, G. E. 1993. Pharmacokinetics of aerosolized amiloride in pediatric patients with mild to moderate cystic fibrosis. Pharmacotherapy 13, 3, 292-293.
22. Sabanathan, K., Castleden, C. M., Adam, H. K., Ryan, J., and Fitzsimons, T. J. 1987a. comparative study of the pharmacokinetics and pharmacodynamics ofatenolol, hydrochlorothiazide and amiloride in normal young and elderly subjects and elderly hypertensive patients. Eur. J. Clin. Pharmacol. 32, 1, 53-60.
23. Smith, A. J. and Smith, R. N. 1973. Kinetics and bioavailability of two formulations of amiloride in man. Br. J. Pharmacokinet. 48, 646-649.
24. Spahn, H., Reuter, K., Mutschler, E., Gerok, W., and Knauf, H. 1987. Pharmacokinetics of amiloride in renal and hepatic disease. J. Clin. Pharmacol. 33, 5, 398-493.
25. Ajayi, A. A., Hockings, N., and Reid, J. L. 1986. Age and the pharmacodynamics of the angiotension converting enzyme inhibitors enalapril and enalaprilat. Br. J. Clin. Pharmacol. 21, 349-357.
26. Gautam, P. C., Vargas, E., and Lye, M. 1987. Pharmacokinetics of lisinopril (MK521) in healthy young and elderly subjects and in elderly patients with cardiac failure. J. Pharm. Pharmacol. 39, 11, 929-931.
27. Hayes, P. C., Plevris, J. N., and Bouchier, I. A. 1989. Pharmacokinetics of enalapril and lisinopril in subjects with normal and impaired hepatic function. J. Hum. Hypertens. 3, 153-158.
28. Hockings, N., Ajayi, A. A., and Reid, J. L. 1986. Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat. Br. J. Clin. Pharmacol. 21, 4, 341-348.
29. Johnston, D. and Duffin, D. 1992. Pharmacokinetic profiles of single and repeat doses of lisinopril and enalapril in congestive heart failure. Am. J. Cardiol. 70, 151C-153C.
30. Lees, K. R. and Reid, J. L. 1987. Age and the pharmacokinetics and pharmacodynamics of chronic enalapril treatment. Clin. Pharmacol. Therp. 41, 6, 597-602.
31. Lees, K. R. and Reid, J. L. 1988. Lisinopril and nifedipine: No acute interaction in normotensives. Br. J. Clin. Pharmacol. 25, 307-313.
32. MacDonald, M. J., Sioufi, A., Howie, C. A., Wade, J. R., and Elliott, H. L. 1993. Effects of age on the pharmacokinetics and pharmacodynamics of single oral doses of benazepril and enalapril. Br. J. Clin. Pharmacol. 36, 205-209.
33. McLean, A. J., Drummer, O. H., Smith, H. J., Froomes, P., and McNeil, J. J. 1989. Comparative pharmacokinetics of enalapril and lisinopril, alone and with hydralazine. J. Hum. Hyperten. 3, 147-151.
34. Mojaverian, P., Rocci Jr., M. L., Vlasses, C., Hoholick, C., Clementi, R. A., and Ferguson, R. K. 1986. Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. J. Pharm. Sci. 75, 4, 395-397.
35. Neubeck, M., Fliser, D., Pritsch, M., Weiber, K., Fliser, M., Nussberger, J., Ritz, E., and Mutschler, E. 1994. Pharmacokinetics and pharmacodynamics of lisinopril in advanced renal failure. Eur. J. Clin. Pharmacol. 46, 537-543.
36. Sica, D. A., Cutler, R. E., Parmer R. J., and Ford, N. F. 1991. Comparison of the steady state pharmacokinetics of fosinopril, lisinopril, and enalapril in patients with chronic renal insufficiency. Clin. Pharmacokinet. 20, 420-427.
37. Shionoiri, H., Minamisawa, K., Ueda, S., Abe, Y., Ebina, T., Sugimoto, K., Matsukawa, T., Gotoh, E., and Ishii, M. 1990. Pharmacokinetics and antihypertensive effects of lisinopril in hypertensive patients with normal and impaired renal function. J. Cardiovas. Pharmacol. 16, 4, 594-600.
38. Till, A. E., Dickstein, K., Aarsland, T., Gomez, H. J., Gregg, H., and Hichens, M. 1989. The pharmacokinetics of lisinopril in hospitalized patients with congestive heart failure. British J. Clin. Pharm. 27, 199-204.
39. van Schaik, B. A., Geyskes, G. G., van der Wouw, P. A., van Rooij, H. H., and Porsius A. J. 1988. Pharmacokinetics of lisinopril in hypertensive patients with normal and impaired renal function. Eur. J. Clin. Pharmacol. 34, 1, 61-65.
40. Weisser, K., Schloos, J., Jakob, S., Muhlberg, W., Platt, D., and Mutschler, E. 1992. The influence of hydrochlorothiazide on the pharmacokinetics of enalapril in elderly patients. Eur. J. Clin. Pharmacol. 43, 2, 173-177.
41. Bisson, C., St. Laurent, M., Michaud, J. T., and LeBel, M. 1993. Pharmacokinetics and pharmacodynamics of ranitidine and famotidine in healthy elderly subjects: a double-blind, placebo-controlled comparison. Pharmacotherapy 13, 1, 3-9.
42. Halstenson, C. E., Abraham, P. A., Opsahl, J. A., Chremos, A. N., Keane, W. F., and Matzke, G. R. 1987. Disposition of famotidine in renal insufficiency. J. Clin. Pharmacol. 27, 782-787.
43. Inotsume, N., Nishimura, M., Fujiyama, S., Sagara, K., Sato, T., Imai, Y., Matsui, H., and Nakano, M. 1989. Pharmacokinetics of famotidine in elderly patients with and without renal insufficiency and in healthy young volunteers. Eur. J. Clinical Pharmacol. 36, 5, 17-20.
44. James, L. P., Marshall, J. D., Heulitt, M. J., Wells, T. G., Letzig, L., and Kearns, G. L. 1996. Pharmacokinetics and pharmacodynamics of famotidine in children. J. Clin. Pharmacol. 36, 1, 48-54.
45. James, L. P. and Kearns, G. L. 1996. Pharmacokinetics and pharmacodynamics of famotidine in pediatric patients. Clin. Pharmacokinet..31, 2, 103-110.
46. Kraus, G., Krishna, D. R., Chmelarsch, D., Schmid, M., and Klotz, U. 1990. Famotidine. Pharmacokinetic properties and suppression of acid secretion in pediatric patients following cardiac surgery. Clin. Pharmacokinet. 18, 1, 77-81.
47. Kroemer, H. and Klotz, U. 1987. Pharmacokinetics of famotidine in man. Int. J. Clin. Pharmacol., Therp, Toxicol. 25, 8, 458-463.
48. Lin, J. H., Chremos, A. N., Kanovsky, S. M., Schwartz, S., Yeh, K. C., and Kann, J. 1987. Effects of antacids and food on absorption of famotidine. Br. J. Clin. Pharmacol. 24, 551-553.
49. Morgan, M. Y., Stambuk, D., Cottrell, J., and Mann, S. G. 1990. Pharmacokinetics of famotidine in normal subjects and in patients with chronic liver disease. Aliment. Pharmacol. Therp. 4, 1, 83-96.
50. Morgan, M. Y. and Stambuk, D. 1986. Famotidine pharmacokinetics following oral and intravenous administration in patients with liver disease: results of a preliminary study. Postgrad. Med. J. 62(Suppl.) 2, 29-37.
51. Nagita, A., Manago, M., Aoki, S., Mino, M., Suzuki, K., and Ashida, K. 1994. Pharmacokinetics and pharmacodynamics of famotidine in children with gastroduodenal ulcers. Ther. Drug. Monit. 16, 5, 444-149.
52. 2-receptor antagonist, in relation to renal function. Eur. J. Clin. Pharmacol. 28, 327-331.
53. Vincon, G., Baldit, C., Couzigou, P., Demotes-Mainard, F., Elouaer-Blanc, L., Bannwarth, B., and Begaud B. 1992. Pharmacokinetics of famotidine in patients with cirrhosis and ascites. Eur. J. Clin. Pharmacol. 43, 5, 559-562.
54. Yeh, K. C., Chremos, A. N., Lin, J. H., Constanzer, M. L., Kanovsky, S. M., Hucker, H. B., Antonello, J., Vlasses, P., Ryan, J. R., and Williams, R. L. 1987. Single-dose pharmacokinetics and bioavailability of famotidine in man. Results of multicenter collaborative studies. Biopharm. Drug Dispos. 8, 6, 549-560.
55. Alvan, G., Orme, M., Bertilsson, L., Ekstrand, R., and Palmer, L. 1975. Pharmacokinetics of indomethacin. Clin. Pharmacol. Therp. 18, 3, 364-373.
56. Baber, N., Halliday, L. D., van den Heuvel, W. J., Walker, R. W., Sibeon, R., Keenan, J. P., Littler, T., and Orme, M. L. 1979. Indomethacin in rheumatoid arthritis: clinical effects, pharmacokinetics, and platelet studies in responders and nonresponders. Annal. Rheum. Dis. 38, 2, 128-136.
57. Bhat, R., Vidyasagar, D., Fisher, E., Hastreiter, A., Ramirez, J. L., Burns, L., and Evans, M. 1980. Pharmacokinetics of oral and intravenous indomethacin in preterm infants. Dev. Pharmacol. Therp. 1, 101-110.
58. Bianchine, J. R., Procten, R. R., and Thomas, F. B. 1982. Piroxicam, aspirin, and gastrointestinal blood dose. Clin. Pharmacol. Therp. 32, 247-252.
59. Brewer, E. J., Jr. 1968a. Comparative evaluation of indomethacin, acetaminophen and placebo as antipyretic agents in children. Arthritis Rheumatism 11, 5, 645-651.
60. Bruguerolle, B., Barbeau, G., Belanger, P. M., and Labrecque, G. 1986. Pharmacokinetics of a sustained-release product of indomethacin in the elderly. Gerontology 32, 5, 277-285.
61. Caille, G., Du Souich, P., Gervais, P., and Besner, J. G. 1987. Single dose pharmacokinetics of ketoprofen, indomethacin, and naproxen taken alone or with sucralfate. Biopharm. Drug Dispos. 8, 2, 173-183.
62. Dahl, S. L. and Ward, J. R. 1982. Pharmacology, clinical efficacy, and adverse effects of piroxicam, a new nonsteroidal anti-inflammatory agent. Pharmacotherapy 2, 80-89.
63. Guissou, P., Cuisinaud, G., Llorca, G., Lejeune, E., and Sassard, J. 1983. Chronopharmacokinetic study of prolonged release form of Indomethacin. Eur. J. Clin. Pharmacol. 24, 667-670.
64. Hasan, M. M., Najib, N. M., and Muti, H. Y. 1994a. Pharmacokinetic study on two sustained-release formulations of indomethacin in normal subjects following a single dose administration. J. Clin. Pharm. Therp. 19, 295-299.
65. Jones, R. W., Collins, A. J., Notarianni, L. J., and Sedman, E. 1991. The comparative pharmacokinetics of acemetacin in young subjects and elderly patients. Br. J. Clin. Pharmacol. 31, 5, 543-545.
66. Kwan, K. C., Breault, G. O., Umbenhauer, E. R., McMahon, F. G., and Duggan, D. E. 1976. Kinetics of indomethacin absorption, elimination, and enterohepatic circulation in man. J. Pharmacok. Biopharm. 4, 3, 255-272.
67. McElnay, J. C., Passmore, A. P., Crawford, V. L. S., McConnell, J. G., Taylor, I. C., and Walker, F. S. 1992. Steady state pharmacokinetic profile of indomethacin in elderly patients and young volunteers. Eur. J. Clin. Pharmacol. 43, 77-80.
68. Rowe, J. S. and Carless, J. E. 1981. Comparison of the in-vitro dissolution behaviour of various indomethacin formulations with their in-vivo bioavailability. J. Pharm. Pharmac. 33, 561-564.
69. Seideman, P. 1991. Lack of effect of paracetamol on the pharmacokinetics of indomethacin and paraceetamol in humans. J. Clin. Pharmacol. 31, 9, 804-807.
70. Waller, E. S. 1983. Evaluation of new indomethacin dosage forms. Pharmacotherapy 3, 324-333.
71. Chiba, K., Suganuma, T., Ishizaki, T., Iriki, T., Shirai, Y., Naitoh, H., and Hori, M. 1985. Comparison of steady-state pharmacokinetics of valproic acid in children between monotherapy and multiple antiepileptic drug treatment. J. Pediatr. 106, 4, 653-658.
72. Cloyd, J. C., Fischer, J. H., Kriel, R. L., and Kraus, D. M. 1993. Valproic acid pharmacokinetics in children. IV. Effects of age and antiepileptic drugs on protein binding and intrinsic clearance. Clin. Pharmacol. Ther. 53, 1, 22-29.
73. Cloyd, J. C., Kriel, R. L., Fischer, J. H., Sawchuk, R. J., and Eggerth, R. M. 1983. Pharmacokinetics of valproic acid in children. I. Multiple antiepileptic drug therapy. Neurology. 33, 2, 185-191.
74. Cloyd, J. C., Kriel, R. L., and Fischer, J. H. 1985. Valproic acid pharmacokinetics in children. II. Discontinuation of concomitant antiepileptic drug therapy. Neurology 35, 11, 1623-1627.
75. Kriel, R. L., Fischer, J. H., Cloyd, J. C., Green, K. H., and Fraser, G. L. 1986. Valproic acid pharmacokinetics in children: III. Very high dosage requirements. Pediatr. Neurol. 2, 4, 202-208.
76. Rosenfeld, W. E., Liao, S., Kramer, L. D., Anderson, G., Palmer, M., Levy, R. H., and Nayak, R. K. 1997. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 38, 3, 324-333.